SciELO - Scientific Electronic Library Online

 
vol.39 número3Normas brasileiras e efeitos de idade e escolaridade no Teste Hayling e no Teste de TrilhasAdaptação transcultural da Sport Anxiety Scale-2 (SAS-2) para o contexto brasileiro índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Trends in Psychiatry and Psychotherapy

versão impressa ISSN 2237-6089versão On-line ISSN 2238-0019

Resumo

ASCOLI, Bruna M. et al. Cell therapy in the treatment of bipolar mania in an animal model: a proof of concept study. Trends Psychiatry Psychother. [online]. 2017, vol.39, n.3, pp.196-201.  Epub 15-Maio-2017. ISSN 2238-0019.  https://doi.org/10.1590/2237-6089-2016-0074.

Introduction

The rationale of mesenchymal stem cells (MSCs) as a novel therapeutic approach in certain neurodegenerative diseases is based on their ability to promote neurogenesis. Hippocampal atrophy has been related to bipolar disorder (BD) in preclinical, imaging and postmortem studies. Therefore, the development of new strategies to stimulate the neurogenesis process in BD is crucial.

Objectives

To investigate the behavioral and neurochemical changes induced by transplantation of MSCs in a model of mania-like behavior induced by lisdexamfetamine dimesylate (LDX).

Methods

Wistar rats (n=65) received one oral daily dose of LDX (10 mg/kg) or saline for 14 days. On the 8th day of treatment, the animals additionally received intrahippocampal saline or MSC (1 µL containing 25,000 cells) or lithium (47.5 mg/kg) as an internal experimental control. Two hours after the last administration, behavioral and neurochemical analyses were performed.

Results

LDX-treated rats had increased locomotor activity compared to saline-saline rats (p=0.004), and lithium reversed LDX-related hyperactive behavior (p<0.001). In contrast, the administration of MSCs did not change hyperlocomotion, indicating no effects of this treatment on LDX-treated rats (p=0.979). We did not find differences between groups in BDNF levels (p>0.05) in the hippocampus of rats.

Conclusion

Even though these results suggest that a single intrahippocampal injection of MSCs was not helpful to treat hyperactivity induced by LDX and neither influenced BDNF secretion, we cannot rule out the possible therapeutic effects of MSCs. Further research is required to determine direct effects of LDX on brain structures as well as in other pathophysiological targets related to BD.

Palavras-chave : Mesenchymal stem cells; cellular therapy; bipolar disorder; mania; neurogenesis; hippocampus.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )